HIV Associated Conditions

HIV associated conditions are a broad spectrum of infective, malignant and other conditions occurring with increased frequency or severity in the context of HIV infection.

The pattern and risk of individual conditions is closely related to the degree of immunosuppression as reflected by the CD4 count. This provides an essential clinical framework for anticipating and screening for specific complications.

The fundamental principle underlying management is that effective antiretroviral therapy, through immune reconstitution, remains the single most important intervention for both treating and preventing the great majority of these associated conditions.

Framework by CD4 count

• At CD4 counts above 500 cells per microlitre, patients are generally at low risk of opportunistic infection. They remain at risk of the general infections affecting the immunocompetent population, sometimes with somewhat increased severity.
• At CD4 counts between 200 and 500 cells per microlitre, risk increases for bacterial infections, oral and vaginal candidiasis, and reactivation of latent tuberculosis. Recurrent bacterial pneumonia is a recognised AIDS defining condition when recurrent.
• Risk of certain malignancies, including Kaposi sarcoma and non Hodgkin lymphoma, is also increased.
• At CD4 counts between 100 and 200 cells per microlitre, Pneumocystis pneumonia risk rises substantially, warranting prophylaxis initiation at this threshold. Tuberculosis risk remains elevated, with a tendency toward more atypical and disseminated presentation at lower CD4 counts.
• At CD4 counts below 100 cells per microlitre, toxoplasma encephalitis, cryptococcal meningitis, and progressive multifocal leukoencephalopathy become significant risks.
• Cytomegalovirus disease (particularly retinitis) and disseminated Mycobacterium avium complex infection become increasingly relevant at CD4 counts below 50 cells per microlitre.

• The clinical presentation of any specific associated condition follows the pattern of the underlying condition. The key distinguishing feature in the HIV positive population is frequently a greater propensity for atypical, disseminated, or more severe presentation compared with the immunocompetent population, reflecting the degree of underlying immune impairment.
• Constitutional symptoms including unexplained fever, weight loss and night sweats are common. They occur either in isolation or as a prodrome to a more specific complication, and should prompt systematic evaluation according to the CD4 count and associated risk profile.
• A previously undiagnosed HIV infection may first present with one of these associated conditions. Any patient presenting with an opportunistic infection, an AIDS defining malignancy, or an atypical or unusually severe presentation of a common infection should have HIV testing as part of the diagnostic evaluation, given the substantial benefit of early diagnosis and treatment initiation.
• Immune reconstitution inflammatory syndrome is a paradoxical clinical worsening or unmasking of a previously subclinical infection. It occurs in the weeks following initiation of antiretroviral therapy as immune function begins to recover, and is an important and increasingly recognised phenomenon.
• It requires careful clinical recognition rather than being mistaken for treatment failure or an entirely new, unrelated process. In some cases it needs specific management (including corticosteroid therapy for severe manifestations).

• Regular CD4 count and HIV viral load monitoring forms the foundation of ongoing risk assessment and screening strategy in every patient with confirmed HIV infection. It guides the prophylactic measures and heightened clinical vigilance appropriate to the individual patient's current level of immune function.
• Diagnostic evaluation of any specific suspected associated condition follows the approach detailed under that individual condition. Use a lower threshold for pursuing investigation, given the generally higher prior probability of significant pathology in HIV related immunosuppression.
• Conversely, a broader differential diagnosis is frequently required, given the range of atypical organisms and presentations relevant to this population.
• Consider HIV testing (fourth generation antigen antibody combination assay, with confirmatory testing where positive) in any patient presenting with a condition suggestive of significant immunosuppression, an AIDS defining illness, or risk factors for HIV acquisition. Establishing the underlying diagnosis guides both immediate management and long term care.

• Initiation or optimisation of effective antiretroviral therapy is the fundamental, overarching management priority. Sustained viral suppression and CD4 count recovery reduce the risk of the full spectrum of associated opportunistic and malignant complications.
• Current guidance generally recommends prompt initiation of antiretroviral therapy in every newly diagnosed patient regardless of CD4 count, given demonstrated individual and public health benefit from earlier treatment.
• Specific antimicrobial or other targeted treatment of any confirmed associated condition follows the established management approach for that condition.
• Drug interactions between antiretroviral therapy and other medications are common and clinically significant. Review carefully, ideally with specialist HIV pharmacy or infectious disease input, whenever new medications are introduced.
• Primary prophylaxis against specific opportunistic infections is indicated at defined CD4 count thresholds, as detailed under the individual conditions. Co trimoxazole is used for Pneumocystis pneumonia and toxoplasmosis prophylaxis below relevant CD4 thresholds, and azithromycin for Mycobacterium avium complex prophylaxis at very low CD4 counts.
• Prophylaxis is generally discontinued once sustained CD4 count recovery above the relevant threshold has been achieved on effective antiretroviral therapy.
• Timing of antiretroviral therapy initiation relative to treatment of a newly diagnosed opportunistic infection requires careful individualised consideration. It balances the benefit of earlier immune reconstitution against the risk of immune reconstitution inflammatory syndrome.
• Guidance varies by the opportunistic infection identified. Earlier initiation is generally used for most conditions.
• Specific delays are recommended for cryptococcal and tuberculous meningitis, given a particularly severe and potentially life threatening risk of immune reconstitution inflammatory syndrome affecting the central nervous system in these contexts.
• Screening for and management of the specific malignancies associated with HIV infection is an important component of ongoing HIV care. These are Kaposi sarcoma, non Hodgkin lymphoma, and, in women, an increased risk of cervical dysplasia and malignancy given the shared human papillomavirus association, warranting regular cervical screening.
• Multidisciplinary, specialist HIV service involvement underpins long term management of this now generally well controlled, chronic condition in patients receiving effective, sustained antiretroviral therapy.
• Regular structured review incorporates monitoring of viral load, CD4 count, medication adherence and tolerability.
• Include age and risk factor appropriate general health screening (cardiovascular risk, bone health), given that both the disease itself and certain antiretroviral agents carry relevant long term implications.